ClinicalTrials.gg
RecruitingNCT07284602SURPASS-IPFUpdated Oct 23, 2026

Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 3 interventional study of Deupirfenidone and Pirfenidone (PFD) in Idiopathic Pulmonary Fibrosis (IPF), sponsored by PureTech. Recruiting at 18 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by PureTech · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 23, 2026First site in Canada8 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,100
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis — 2 open to participants now, 3 under way, 1 of them phase 3. pirfenidone · Idiopathic Pulmonary Fibrosis.

Planned enrollment
Largest of 21
1,100 · median 89
Started
2026
with 1 other
Phase 3
6 of 21
1 open now
Registered
21st of 21
by date
Lead sponsor
2 of 21
PureTech

Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, this one has the largest planned enrollment, is one of 2 that started in 2026, is one of 6 in phase 3, and was the 21st registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

2 of the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About pirfenidone

pirfenidone: first FDA approval 2014 (ESBRIET), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

This is a study for adults with a lung disease called idiopathic pulmonary fibrosis. The main purpose of this study is to look at how well deupirfenidone improves lung function and how safe it is for people with idiopathic pulmonary fibrosis (IPF) when compared with pirfenidone. Participants may have been treated with an approved antifibrotic drug for up to a year in the past, but they cannot be on background antifibrotic treatment during this study. Participants will be randomly assigned (meaning by chance) to take either deupirfenidone or pirfenidone 3 times a day, and neither a participant nor their study team will know which study drug participants are on. Participants will be in the study for up to approximately 3 years. During the first year, participants visit the study site up to ten times and afterwards they visit the site every three months. All participants will remain on blinded study drug until the last participant has completed Week 52 Visit. They will have lung function tests, a check of their health, and will tell the study team about any unfavorable effects.

Read the detailed description

This is a Phase 3 randomized, double-blind, head-to-head study comparing deupirfenidone 825 mg TID to pirfenidone 801 mg TID over 52 weeks of treatment in participants with IPF who are not on background therapy. This study is designed to demonstrate superior efficacy of deupirfenidone over pirfenidone as well as support the overall safety profile of deupirfenidone. Prospective participants will initially enter the Screening Period to determine study eligibility (Section 5). Eligible participants will be randomized 1:1 to receive either blinded deupirfenidone 825 mg TID or pirfenidone 801 mg TID as part of the Double-Blind Treatment Period for at least 52 weeks (Period 1). Depending on when participants enter the study, they may continue being treated for up to two more years (Period 2).

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis (IPF)

Keywords

  • Idiopathic Pulmonary Fibrosis
  • IPF
  • Pulmonary Fibrosis
  • Deupirfenidone
  • Pirfenidone
  • Lung Disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is ≥40 years of age at the time of .
  • Meets the diagnostic criteria of IPF American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Society (ALAT) 2022 guidelines.
  • Has a maximum time from initial IPF diagnosis of 7 years.
  • Has no prior exposure to pirfenidone or LYT-100.
  • Has definite or probable unusual interstitial pneumonia (UIP) on HRCT, performed within 12 months prior to Visit 1 and confirmed by the central reader.
  • Has an FVC ≥45% of predicted normal at Visit 1.

Exclusion criteria

Exclusion Criteria:

  • Has, in the opinion of the Investigator, significant clinical worsening of IPF between Visit 1 and Visit 2 (eg, hospitalization, clinically significant respiratory event).
  • Has been hospitalized within 3 months prior to Visit 1 for acute exacerbation of IPF or other significant respiratory complication.
  • Has prebronchodilator (FEV1)/FVC \<0.7 at Visit 1.
  • Has a greater extent of emphysema vs fibrosis on the most recent HRCT scan as confirmed by the central reader.
  • Has a diagnosis of any condition that could be an explanation for interstitial lung disease (ILD).
  • Has a major extrapulmonary condition that could affect spirometry.
  • Has a current diagnosis of other relevant respiratory disorders.
  • Has significant pulmonary hypertension (PH).
  • Has had a lung transplant.
  • Has cardiovascular disease.
  • Has underlying chronic liver disease/impairment.
  • Has relevant chronic or acute infections including active viral hepatitis or poorly controlled .
  • Has had any major surgical procedures performed within 6 weeks prior to Visit 1 or is planning to have a major surgical procedure during the study.
  • Has any documented active or suspected or history of malignancy within 5 years prior to Visit 1.
  • Has any of the following laboratory abnormalities at Visit 1:

    • (AST) or Alanine aminotransferase (ALT) >1.5 × (ULN).
    • Total >1.5 × ULN. Exceptions may be made on a case-by-case basis for participants with Gilbert's syndrome in consultation with the Medical Monitor.
    • \<30 mL/min calculated by Cockcroft-Gault formula.
  • Is currently taking prednisone at a steady dose >10 mg/day or equivalent (a steady dose ≤10 mg/day is not exclusionary but the individual must be on a stable dose for at least 30 days prior to Visit 2).
  • Use of any tobacco or combustible cannabis products within 3 months prior to Visit 1 or is unable to refrain from use during the trial.
  • Has known symptoms of dysphagia, difficulty in swallowing capsules or tablets, or has had a total gastrectomy.
  • Is currently enrolled in another clinical study (except observational/registry or biobank studies) or has used any drug or device within 90 days prior to Visit 1.
  • Has ever received stem cell therapy for the treatment of pulmonary fibrosis.
  • Is currently pregnant, breastfeeding, or is planning to become pregnant during the study.
  • Has had any prior exposure to LYT-100 or pirfenidone (even one dose).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,100 participants (estimated)

Study arms

  • Experimental
    Active

    deupirfenidone 825 mg TID

    Drug: Deupirfenidone

  • Active comparator
    Active Comparator

    pirfenidone 801 mg TID

    Drug: Pirfenidone (PFD)

Interventions

06

What researchers measure

Primary outcomes

  1. Absolute change in forced vital capacity (FVC) measured in mL

    Evaluate the efficacy of deupirfenidone compared with pirfenidone on reduction in lung function decline in participants with IPF

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Absolute change in FVC percent predicted (FVCpp)

    Evaluate the efficacy of deupirfenidone compared with pirfenidone on reduction in lung function decline relative to individual predicted normal lung function

    Time frame: Baseline to Week 52

07

Study locations

18 of 18 sites recruiting
08

References and documents

Publications

  • Maher TM, Hamblin MJ, Choi WI, Case AH, Tomos IP, Tzouvelekis AE, Shore JE, Bergna MA, Golod D, Elenko E, Zhang Y, Graham CS, Song JW, Kulkarni T; and the ELEVATE IPF Investigators. Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial. Am J Respir Crit Care Med. 2026 Aug 1;212(8):1761-1769. doi: 10.1093/ajrccm/aamag155. PubMed 42085224 ↗

Individual participant data

Plan to share: No — Patient data protection laws in participating countries do not allow for IPD data sharing.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Nov 2029, 41 months after the start.

Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's planned 41 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2025
First posted
Dec 16, 2025
StartActual
Jun 26, 2026
Primary completionEst.
Nov 2029
CompletionEst.
Dec 2029
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added — first site in Canada
Show 8 added (6 United States, 2 Canada)
  • Harmony Medical Research Institute, Inc · Hialeah, United States
  • Clinical Research Specialists, LLC · Kissimmee, United States
  • Pulmonix LLC · Greensboro, United States
  • StatCare Pulmonary Consultants · Knoxville, United States
  • Horizon Clinical Research Group. · Cypress, United States
  • Renovatio Clinical · El Paso, United States
  • Dynamic Drug Advancement Limited · Ajax, Canada
  • Dr. Syed Anees Medicine Professional Corporation · Windsor, Canada
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    8 sites added — first site in Canada
    Show 8 added (6 United States, 2 Canada)
    • Harmony Medical Research Institute, Inc · Hialeah, United States
    • Clinical Research Specialists, LLC · Kissimmee, United States
    • Pulmonix LLC · Greensboro, United States
    • StatCare Pulmonary Consultants · Knoxville, United States
    • Horizon Clinical Research Group. · Cypress, United States
    • Renovatio Clinical · El Paso, United States
    • Dynamic Drug Advancement Limited · Ajax, Canada
    • Dr. Syed Anees Medicine Professional Corporation · Windsor, Canada
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07284602
Lead sponsor
PureTech
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Jun 26, 2026
Primary completion
Nov 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirfenidone

Start the discussion